Literature DB >> 8609807

Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited.

P A Berg1, R Klein.   

Abstract

Methods for the evaluation of the four antimitochondrial antibody subtypes in primary biliary cirrhosis - anti-M2, -M4, -M8, -M9 - are described. The importance of the application of different preparations for the demonstration of complement fixing antibodies and the detection of antibodies by ELISA or Western blotting is emphasized. Complement fixing antigens can be prepared by discontinuous isopynic sucrose density gradient centrifugation using mitochondrial subfractions derived with from beef heart (M2), rat liver (M4), or pig kidney (M8). Anti-M9 antibodies do not fix complement. For ELISA, the pyruvate dehydrogenase or the ATPase-associated antigen fraction (M2), the sulfite oxidase fraction (M4), and the chromatographically purified M8-fraction should be used. The same antigen fractions are suitable for Western blotting, but anti-M4 and anti-M8 by ELISA and Western blotting a purified fraction prepared from rat liver has to be applied. Correlating antimitochondrial antibody-subtypes with clinical condition and the natural course, there is convincing evidence that especially the presence of complement fixing antibodies against the subtypes M2, M4, and M8 is a reliable indicator for a more active course. Patients expressing only anti-M9 (without anti-M2) have biochemically all the typical features also found in classical anti-M2 positive primary biliary cirrhosis patients, but seem not to advance to late stages. Since these antimitochondrial antibody-subtypes are present even in very early stages stages without changing their pattern during the course, antimitochondrial antibody-profiles can also be taken as early prognostic parameters. The evaluation of the immunological activity by antimitochondrial antibody-subtype testing may further facilitate the decision whether therapy with ursodeoxycholic acid should be combined with steroids and/or immunosuppressive agents. The role of mitochondrial autoantigens in the induction of this chronic destructive bile duct process is also discussed. The concept is put forward that not bile ducts but naive(?) B-cells expose the different mitochondrial antigens, thereby stimulating autoreactive T-cells to provide a second signal for antibody production. The degree of breakage of tolerance to the different mitochondrial epitopes may be one crucial factor which determines the diversity of antimitochondrial antibody-subtypes in patients with primary biliary cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8609807     DOI: 10.1111/j.1600-0676.1995.tb00687.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  10 in total

1.  Anti-mitochondrial antibodies in patients with dilated cardiomyopathy (anti-M7) are directed against flavoenzymes with covalently bound FAD.

Authors:  A Otto; I Stähle; R Klein; P A Berg; S Pankuweit; R Brandsch
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

2.  Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments.

Authors:  Palak J Trivedi; Sue Cullen
Journal:  Hepatol Int       Date:  2012-03-20       Impact factor: 6.047

Review 3.  Primary biliary cirrhosis: what do autoantibodies tell us?

Authors:  Chao-Jun Hu; Feng-Chun Zhang; Yong-Zhe Li; Xuan Zhang
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

4.  Catalytic domain of PDC-E2 contains epitopes recognized by antimitochondrial antibodies in primary biliary cirrhosis.

Authors:  Sandra Braun; Christoph Berg; Sandra Buck; Michael Gregor; Reinhild Klein
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 5.  The role of mitochondria in rheumatic diseases.

Authors:  Yann L C Becker; Bhargavi Duvvuri; Paul R Fortin; Christian Lood; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2022-09-29       Impact factor: 32.286

6.  Demonstration of autoantibodies to recombinant human sulphite oxidase in patients with chronic liver disorders and analysis of their clinical relevance.

Authors:  B Preuss; C Berg; F Altenberend; M Gregor; S Stevanovic; R Klein
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

Review 7.  [Primary biliary liver cirrhosis and overlap syndrome. Diagnosis and therapy].

Authors:  C P Strassburg; M P Manns
Journal:  Internist (Berl)       Date:  2004-01       Impact factor: 0.743

8.  [Multiple autoimmune syndrome. Reynolds-syndrome (acral scleroderma, primary biliary cirrhosis, Sjögren syndrome) associated with the lupus erythematosus/lichen planus overlap syndrome].

Authors:  F B Müller; W Groth; G Mahrle
Journal:  Hautarzt       Date:  2004-05       Impact factor: 0.751

9.  A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids.

Authors:  R Olin; R Klein; P A Berg
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

10.  Anti-mitochondrial autoantibodies in systemic lupus erythematosus and their association with disease manifestations.

Authors:  Yann Becker; Renée-Claude Loignon; Anne-Sophie Julien; Geneviève Marcoux; Isabelle Allaeys; Tania Lévesque; Emmanuelle Rollet-Labelle; Hadrien Benk-Fortin; Nathalie Cloutier; Imène Melki; Lihi Eder; Éric Wagner; Martin Pelletier; Hassan El Hajj; Marie-Ève Tremblay; Clémence Belleannée; Marie-Josée Hébert; Mélanie Dieudé; Joyce Rauch; Paul R Fortin; Eric Boilard
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.